BioSpace News Archive

Pramana, Inc. and Techcyte have joined forces to deliver the first intelligent volumetric scanning and digital diagnostics solution for cytology, microbiology, and hematology applications.

Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion, at the European Society of Medical Oncology Congress (ESMO) 2023, held in Madrid, Spain from October 20-24, 2023.

Kye Pharmaceuticals Inc., a Canadian specialty pharmaceutical company, announced its partnership with Hyloris Pharmaceuticals SA, a Belgium-based developer, manufacturer and global supplier of a novel, prescription, oral solution form of atomoxetine.

Immix Biopharma, Inc., announced that effective , Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.

Mustang Bio, Inc. announced that the U.S. Food and Drug Administration has accepted the Company’s Investigational New Drug application of MB-109 for the treatment of recurrent glioblastoma and high-grade astrocytoma.

Utah Medical Products, Inc. despite a difficult third calendar quarter, achieved financial results for nine months 2023 consistent with those anticipated in its beginning of year projections.

Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Steven Vicik , PhD, as Chief Technical Officer (CTO).

ImmunityBio, Inc. announced that the U.S. Food and Drug Administration has accepted for review ImmunityBio’s resubmission of its Biologics License Application for N-803, a first-in-class IL-15 superagonist, plus Bacillus Calmette-Guérin for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease, and considered it as a complete response to the FDA’s May 9, 2023 complete response letter.

Catawba Research, a leading clinical research organization with a goal to become the world’s most trusted CRO, is announcing changes to its executive leadership team.

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2023 results on Thursday, November 9, 2023, after the market close.